Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx (Nasdaq: ARDX) presented a post hoc analysis at the NKF Spring Clinical Meetings (May 7, 2026) evaluating long-term effects of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarkers in dialysis patients with hyperphosphatemia.
Using data from an 18-month extension (NORMALIZE) and a 26-week study (OPTIMIZE), the analysis found no clinically meaningful changes in measured serum electrolytes other than phosphate reduction, and no significant changes in nutrition, body mass, or blood pressure.
Ardelyx (Nasdaq: ARDX) reported Q1 2026 product revenue of $93.4M (38% YoY), with IBSRELA at $70.1M (+58% YoY) and XPHOZAH at $23.3M. The company reaffirmed 2026 revenue guidance for IBSRELA of $410–430M and XPHOZAH $110–120M. Cash and short-term investments were $238.1M as of March 31, 2026. Ardelyx began dosing in the Phase 3 ACCEL trial for CIC, expects enrollment to complete by end-2026, and continues IND-enabling work for RDX10531.
Ardelyx (Nasdaq: ARDX) announced an abstract accepted for a poster at the National Kidney Foundation Spring Clinical Meetings, May 7-10, 2026, in New Orleans. The poster reports long-term effects of XPHOZAH (tenapanor) on serum electrolytes and select nutrition biomarkers in dialysis patients with hyperphosphatemia.
The poster (G-353) will display May 7, 2026, 5:15-7:30 PM CT, and Ardelyx will sponsor a Peer Exchange on May 8 reviewing XPHOZAH mechanism, efficacy, safety, and practical considerations for add-on therapy.
Ardelyx (Nasdaq: ARDX) announced an abstract on IBS-C treatment patterns accepted for poster presentation at Digestive Disease Week (DDW) 2026 in Chicago, May 2-5. The poster (Sa1729) displays May 2, 2026, 12:30-1:30 PM CT. Ardelyx also sponsors a Product Theater on May 5 at 3:00 PM CT.
The Product Theater, led by Darren Brenner, MD, will discuss IBS-C pathophysiology, case studies, and practical strategies to optimize care for adults with IBS-C.
Ardelyx (Nasdaq: ARDX) appointed Felecia W. Ettenberg as Chief Legal Officer effective April 20, 2026. She will lead legal, compliance, regulatory, and government affairs, succeeding Elizabeth Grammer, who is retiring after a 16-year tenure.
Ms. Ettenberg brings more than 25 years of biopharma legal experience, most recently as Senior Vice President and Deputy General Counsel at Bristol Myers Squibb, with responsibility across the U.S. and 40+ international markets.
Ardelyx (Nasdaq: ARDX) will report first quarter 2026 financial results on April 30, 2026 and host a webcast and conference call at 4:30 p.m. Eastern Time. The live webcast, slides and an archived replay will be available in the Investors "Events and Presentations" section at www.ardelyx.com.
Ardelyx (Nasdaq: ARDX) announced the appointment of Rajani Dinavahi, MD as Chief Medical Officer effective April 1, 2026. Dr. Dinavahi brings more than two decades of clinical and development experience across immuno-oncology, autoimmune, metabolic disease, nephrology and transplantation.
Her background includes senior leadership at Atara Biotherapeutics and prior roles at Amgen, with experience advancing programs from early development through Phase 3 and regulatory approval.
Ardelyx (Nasdaq: ARDX) announced the five recipients of the 2026 Derek Forfang Patient Advocate Award on March 12, 2026. Honorees Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts were selected for sustained advocacy on behalf of people with chronic kidney disease.
Recipients will be honored at the National Kidney Foundation Spring Clinical Meetings in New Orleans; the award recognizes contributions in outreach, policy, education and patient-centered research engagement.
Ardelyx (Nasdaq: ARDX) announced publication of a peer‑reviewed post‑hoc analysis titled “Tenapanor is associated with earlier and sustained symptom relief in IBS‑C” in Therapeutic Advances in Gastroenterology.
Pooled data from one Phase 2b and two Phase 3 trials showed increased bowel movement frequency by 2 weeks, meaningful abdominal symptom relief by 4–5 weeks, and greater likelihood of sustained benefit through 12 weeks. No new safety signals were reported; transient mild‑to‑moderate diarrhea was most common.
Ardelyx (Nasdaq: ARDX) announced participation in two investor events in Miami the week of March 10, 2026: the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit.
The company will present at Leerink on March 10 at 4:20 p.m. ET with 1x1 meetings on March 10 and 11. A live webcast will be available on the Events and Presentations page at ir.ardelyx.com; a replay will be hosted for 30 days after the Leerink presentation.